Daily Sepsis Research Analysis
Three papers stand out today: a mechanistic study identifies a non-canonical BRD3 pathway driving inflammatory metabolism in sepsis, a meta-analysis of 18 RCTs clarifies that moderate-dose corticosteroids (often with fludrocortisone) reduce short-term mortality in septic shock, and a multicenter ML model enables early sepsis risk prediction in burn patients using six admission variables.
Summary
Three papers stand out today: a mechanistic study identifies a non-canonical BRD3 pathway driving inflammatory metabolism in sepsis, a meta-analysis of 18 RCTs clarifies that moderate-dose corticosteroids (often with fludrocortisone) reduce short-term mortality in septic shock, and a multicenter ML model enables early sepsis risk prediction in burn patients using six admission variables.
Research Themes
- Immunometabolism and inflammasome regulation in sepsis
- Dose-optimized corticosteroid therapy in septic shock
- Machine learning risk stratification for early sepsis detection in burns
Selected Articles
1. A non-canonical immunometabolic function of BRD3 during sepsis.
The study uncovers a non-canonical BRD3–TRIM21–CREBBP–CREB1 axis that transcriptionally upregulates ACOD1 in myeloid cells, amplifying IL-1β/NLRP3-driven inflammation and worsening outcomes in murine sepsis. Myeloid-specific Brd3 deletion protected mice across four infection models, positioning BRD3 as a promising immunometabolic target in sepsis.
Impact: Identifies a novel, targetable immunometabolic pathway linking BRD3 to inflammasome activation and sepsis pathophysiology with multi-model in vivo validation.
Clinical Implications: Although preclinical, targeting BRD3 or components of the BRD3–TRIM21–CREBBP–CREB1 axis could modulate excessive inflammation in sepsis, informing future drug development.
Key Findings
- BRD3 interacts with TRIM21 to activate CREBBP, leading to acetylation and activation of CREB1 and transcriptional upregulation of ACOD1 in monocytes/macrophages.
- Myeloid-specific Brd3 deletion reduced inflammatory responses and improved outcomes across four murine infection models of sepsis.
- The pathway links BRD3 to NLRP3 inflammasome/IL-1β production, revealing a non-canonical immunometabolic mechanism in sepsis.
Methodological Strengths
- Mechanistic dissection across multiple molecular nodes (BRD3–TRIM21–CREBBP–CREB1–ACOD1)
- Convergent validation in four in vivo murine infection models
Limitations
- Preclinical study without human interventional validation
- Details on translational biomarkers and safety of pathway modulation are not provided
Future Directions: Evaluate pharmacologic BRD3 inhibition or pathway modulation in clinically relevant large-animal models and explore human translational biomarkers of BRD3 activity in sepsis.
Sepsis is a life-threatening condition characterized by a dysregulated host innate immune response to pathogen infection. Here, we identify a pathological role for bromodomain-containing 3 (BRD3) in driving septic shock by upregulating aconitate decarboxylase 1 (ACOD1) in monocytes and macrophages via a non-canonical pathway. Mechanistically, lipopolysaccharide triggers an interaction between BRD3 and tripartite motif containing 21 (TRIM21), which activates CREB binding lysine acetyltransferase (CREBBP) via its E3 ligase activity, facilitating CREBBP's binding to and acetylation of cyclic adenosine monophophate (cAMP)-response-element-binding protein 1 (CREB1). BRD3 then recognizes and phosphorylates acetylated CREB1 at the transcription-activating site, thereby upregulating ACOD1 transcription. In four murine models of infection, myeloid-specific Brd3 deletion (Brd3
2. Corticosteroids for sepsis and septic shock: a meta-analysis of 18 RCTs with dose-stratified and fludrocortisone subgroup evaluation.
Across 7,982 participants, corticosteroids reduced 28-day mortality in sepsis/septic shock, with the clearest benefit at 201–300 mg/day and when paired with fludrocortisone. Findings align with guideline-endorsed use and refine dose/agent choices for clinical practice.
Impact: Provides dose-stratified, agent-specific evidence that clarifies longstanding controversy and supports mortality benefit with moderate-dose regimens, especially with fludrocortisone.
Clinical Implications: Prefer moderate-dose hydrocortisone-equivalent (201–300 mg/day) and consider adding fludrocortisone in septic shock to optimize short-term survival, while individualizing by context.
Key Findings
- Corticosteroids reduced 28-day mortality overall (RR 0.88; 95% CI 0.79–0.98; I²=39%).
- Greatest mortality benefit at 201–300 mg/day hydrocortisone-equivalent dosing (RR 0.86; I²=0%).
- Hydrocortisone plus fludrocortisone was associated with improved outcomes (RR 0.89), with region-specific differences noted.
Methodological Strengths
- PRISMA 2020-compliant meta-analysis with pre-specified dose and agent subgroups
- Random-effects synthesis across 18 RCTs with nearly 8,000 participants
Limitations
- Heterogeneity across trials and potential differences in co-interventions and sepsis definitions
- Limited data on long-term outcomes and adverse effects stratified by dose and regimen
Future Directions: Prospective head-to-head RCTs comparing moderate-dose hydrocortisone alone vs. hydrocortisone plus fludrocortisone and evaluations of long-term safety and functional outcomes.
BACKGROUND: The therapeutic benefit of corticosteroids in managing sepsis and septic shock remains controversial, particularly concerning optimal dosing strategies and the role of adjunctive fludrocortisone. Recent large-scale trials and updated guidelines underscore the need for a dose-stratified synthesis. This meta-analysis aimed to comprehensively evaluate the effects of corticosteroids on short-term mortality in sepsis, with subgroup analyses by steroid type, dosage, and geographic region. METHODS: This study followed the PRISMA 2020 guidelines. Randomized controlled trials (RCTs) comparing corticosteroids with placebo in adult patients with sepsis or septic shock were included. Subgroup analyses were pre-specified for daily hydrocortisone-equivalent dose (≤ 200 mg, 201-300 mg, > 300 mg), steroid type (hydrocortisone alone vs. hydrocortisone plus fludrocortisone), and region (China vs. non-China). Risk ratios (RRs) with 95% confidence intervals (CIs) were synthesized using a random-effects model. RESULTS: Eighteen RCTs comprising 7,982 patients were included. Corticosteroid therapy was associated with reduced 28-day mortality (RR = 0.88; 95% CI: 0.79-0.98; I² = 39%). The 28-day mortality was 31.0% in the corticosteroid group versus 35.5% in the control group.The most pronounced benefit was seen with 201-300 mg/day regimens (RR = 0.86; I² = 0%) and with combination therapy including fludrocortisone (RR = 0.89). Regional analysis showed weaker effects in trials conducted in China. CONCLUSION: Moderate-dose corticosteroids, especially when used in conjunction with fludrocortisone, significantly reduce short-term mortality in septic shock. Findings support guideline-endorsed steroid use and highlight the importance of individualized treatment strategies.
3. Streamlined machine learning model for early sepsis risk prediction in burn patients.
Using six admission-level features from 6,629 burn patients across 11 centers, a Random Forest model achieved AUROC 0.91 and NPV 0.98 for early sepsis risk prediction at ICU entry. The parsimonious, interpretable approach supports immediate risk stratification and timely intervention.
Impact: Demonstrates high-performance, low-burden prediction using routinely available variables, enabling scalable early sepsis detection in a high-risk burn population.
Clinical Implications: Can be embedded into ICU admission workflows for burn patients to triage sepsis risk, prioritize monitoring and prophylactic strategies, and potentially reduce delays in treatment.
Key Findings
- A six-feature Random Forest model (age, TBSA, deep partial-thickness, full-thickness burns, inhalation injury, hypertension) achieved AUROC 0.91 with sensitivity 0.81 and specificity 0.85.
- Negative predictive value was 0.98, supporting safe rule-out for early sepsis risk at ICU admission.
- Model trained and validated on 6,629 patients across 11 centers in the German Burn Registry.
Methodological Strengths
- Multicenter dataset with large sample size and cross-validated ML pipelines
- Parsimonious feature set using only admission-level variables enhances deployability
Limitations
- Retrospective registry-based development without prospective impact evaluation
- Generalizability beyond participating centers and healthcare systems remains to be tested
Future Directions: Prospective external validation and impact studies assessing clinical integration, alert thresholds, and effects on time-to-treatment and outcomes.
Sepsis is the leading cause of mortality in burn patients, yet early identification remains difficult due to persistent hyperinflammatory responses and altered baseline physiology. We developed a streamlined machine learning model for early sepsis risk prediction in burn patients using data from 6629 patients across 11 centers participating in the German Burn Registry. The model was trained using only six admission-level variables (age, burned body surface area, deep partial-thickness burns, full-thickness burns, inhalation injury, and hypertension), selected through multiple feature selection methods and evaluated using cross-validated machine learning pipelines. The final Random Forest model achieved an AUROC of 0.91, sensitivity of 0.81, specificity of 0.85, and a negative predictive value of 0.98, enabling reliable early risk stratification immediately upon ICU admission. By relying solely on admission-level variables, this model offers a reliable and interpretable solution for early sepsis risk detection in burn patients, supporting timely interventions and potentially improving critical care outcomes.